All Companies articles – Page 4
-
NewsLive-cell liquid biopsy study aims to transform cancer treatment
Vortex Liquid Biopsy Solutions has launched a new clinical study with The Doctors Laboratory to assess how its live-cell liquid biopsy technology could change cancer monitoring and treatment.
-
NewsLife sciences face ‘scientific content crisis’ in AI adoption
A new survey by the Pistoia Alliance reveals a growing ‘scientific content crisis’ in life sciences, showing that incomplete data and weak governance are limiting the accuracy and adoption of AI in research and development.
-
ArticleRNA that knows where to go: the rise of targeted delivery
What if RNA medicines could be guided directly to tumours, sparing healthy tissue and reducing side effects? Advances in targeted delivery are bringing that vision closer to reality.
-
ArticleThe partnership changing the pace of radiopharmaceutical development
A new collaboration between Crown Bioscience and Medicines Discovery Catapult is bringing advanced tumour models together with world-class imaging and radiochemistry to accelerate the development of next-generation radiopharmaceuticals.
-
ArticleRedesigning paclitaxel: expanding the therapeutic window through oral delivery
The potent chemotherapy drug paclitaxel is widely employed for various cancers despite toxicity and efficacy challenges. Maite Agüeros reveals how novel nanoparticle technology has enabled oral delivery of the drug – showing promising signs of improved tolerability and treatment success.
-
ArticleThe mother of invention: from steam engines to AI-designed drugs
Every great leap in history started with a single, urgent need. Now AI is emerging as the next great engine of invention, transforming the future of medicine faster than ever imagined.
-
NewsNew mRNA therapy targets drug-resistant pneumonia
A new mRNA therapy that prompts the body to produce bacteria-killing ‘peptibodies’ has shown early success in preclinical models, offering a potential new tool in the fight against antibiotic-resistant pneumonia.
-
NewsSamsung invests in Phrontline to advance next-gen ADC therapies
Samsung Life Science Fund has made a strategic equity investment in clinical-stage biotechnology company Phrontline Biopharma, supporting the development of next-generation antibody-drug conjugates (ADCs).
-
ArticleMapping the genome in 3D to reveal new drug targets
Find out how a three-dimensional view of the genome is giving scientists a clearer picture of disease biology and revealing new opportunities for targeted therapies.
-
OpinionMaking science run at the speed of thought: the reality of AI in drug discovery – Part 2
Can automation and AI finally make science run at the speed of thought? Eric Ma shares how disciplined systems, not new models, will drive the next wave of discovery.
-
NewsRhosin shown to reverse blood stem cell ageing
Scientists have discovered that the drug Rhosin can rejuvenate ageing blood stem cells by inhibiting a key protein linked to cellular decline, providing a potential new strategy to combat age-related diseases.
-
ArticleFast, scalable free energy prediction with nonequilibrium switching
Nonequilibrium switching (NES) offers a faster, more scalable way to predict how strongly drugs bind to their targets. By replacing slow equilibrium simulations with rapid, parallel transitions, NES delivers accurate free energy predictions at speed.
-
ArticleMapping lipid pockets to drug the undruggable proteome
Tasca Therapeutics is using chemical proteomics to map lipid-binding pockets on proteins. By targeting auto-palmitoylation, the company aims to turn previously undruggable cancer drivers into viable therapeutic targets.
-
ArticleAdvancing disease biomarker research with EV multiplex profiling
Vanitha Margan, Global Product Manager for Bio-Plex Multiplex Immunoassays at Bio-Rad Laboratories, reveals how multiplexing is being used to realise the full potential of extracellular vesicles in disease monitoring.
-
NewsNew stealth CRISPR method reduces immune interference in tumours
Researchers have developed a novel CRISPR method that evades the immune system in mice, allowing scientists to study tumour growth and metastasis more accurately.
-
ArticleAI and policy reform set to reshape UK drug development
BCG’s Chris Meier outlines how advances in AI and new UK policies could accelerate drug development, streamline clinical trials and strengthen the country’s life sciences sector.
-
NewsRecycled nuclear fuel to power new cancer treatments in the UK
The UK is set to turn recycled nuclear fuel into new cancer treatments, thanks to a £18.8 million investment in a project using lead-212 to develop Targeted Alpha Therapies.
-
ArticleTackling the organ shortage through vascular bioengineering
Frontier Bio’s vascular bioengineering research connects tissue modelling with graft development to advance regenerative medicine and drug discovery.
-
ArticleTransforming central labs with automation and AI: setting new standards for modern trials
Demands on central laboratories are consistently increasing, heightening the challenge to deliver operational excellence and the highest standard of scientific integrity with both speed and agility. ICON Laboratories is transforming the way we leverage data and intelligent operational models to meet evolving trial needs.
-
NewsPDX models: a new tool for colorectal cancer research
Patient-derived xenograft models are reshaping colorectal cancer research by preserving the complexity of real tumours, potentially helping scientists to develop new therapies in the future.